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Abstract
Pregnancy is hypercoagulable state. The field of thrombophilia; the tendency to thrombosis, has
been developed rapidly and has been linked to many aspects of pregnancy. It is recently that severe
pregnancy complications such as severe preeclampsia intrauterine growth retardation abruptio
placentae and stillbirth has been shown to be associated with thrombophilia. Recurrent miscarriage
and has also been associated with thrombophilia. Finally, thromboembolism in pregnancy as in the
non-pregnant state is linked to thrombophilia. In this review all aspects of thrombophilia in
pregnancy are discussed, and also all prophylactic and therapeutic implications.
Thrombophilias are inherited or acquired conditions
which predispose an individual to thromboembolism.
Deficiencies of protein S C and antithrombin are rare and
each of them is found in about 3% of patients with throm-
bosis. Recently, three important inherited thrombophilias
were discovered which are responsible of the majority of
thromboembolic events in patients with otherwise no
apparent risk for thrombosis. Resistance to activated pro-
tein C caused by an adenine 506 guanine (A506G) muta-
tion in factor V (factor V Leiden) has been linked with an
increased risk for venous thromboembolism [1-3]. Heter-
ozygosity for the factor V (FV) Leiden mutation is found
in about 5% of the population and the mutation is
responsible of 20–30% of venous thromboembolism
events. A recently described guanine 20210 adenine
mutation in prothrombin is associated with higher
plasma prothrombin concentrations and increased risk
for venous thromboembolism [4] and cerebral-vein
thrombosis [5]. Homozygosity for the cytosine 677 thym-
ine (C677T) mutation in methylenetetrahydrofolate
reductase (MTHFR) results in decreased synthesis of 5-
methyltetrahydrofolate, the primary methyl donor in the
conversion of homocysteine to methionine and the result-
ing increase in plasma homocysteine concentrations is a
risk factor for thrombosis [6,7]. The mutation is responsi-
ble for reduced MTHFR activity and is the most frequent
cause of mild hyperhomocysteinemia and can be found in
5–15% of the population.
Homocysteine is an independent risk factor for athero-
sclerosis, stroke, peripheral vascular disease and cardio-
vascular diseases [8,9]. Homocysteine concentrations are
affected by nutrition. A deficiency in folate, B-6, and/or B-
I2 causes elevation of homocysteine. Homocysteine con-
centrations are also affected by genetics such as cystathio-
nine beta-synthase deficiency (10) and C677T MTHFR
gene mutation [7]. Hyperhomocysteinemia promotes vas-
cular damage by several mechanisms. Many of the
endothelial vascular changes associated with hyperhomo-
cysteinemia can be found in preeclampsia [11-15].
The risk of venous thromboembolism (VTE) associated
with acquired and inherited thrombophilias is amplified
by other risk factors, for example, the post-surgical state
and immobilization. Recent evidence suggests that the
risk of maternal VTE in cases with underlying
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thrombophilia is substantially increased. The risk of VTE
in pregnant women may be further amplified by the type
of underlying genetic predisposition, like, homozygosity
for a mutation, the presence of multiple mutations (mul-
tigenic defects) or thrombophilic anomalies [16-19].
Thrombophilia and adverse pregnancy outcome
Preeclampsia, abruptio placenta, intrauterine growth
restriction (IUGR) and intrauterine fetal death (IUFD)
greatly contribute to maternal and fetal morbidity and
mortality. Their causes are unknown, but all of them may
be associated with abnormal placental vasculature and
disturbances of hemostasis leading to inadequate mater-
nal-fetal circulation [11-15,20,21].
The etiology of preeclampsia is unknown. It is associated
with abnormal placental development and disturbances
of hemostasis leading to inadequate fetomaternal circula-
tion. Recent data suggest that endothelial dysfunction,
vasoconstriction, placental ischemia and enhanced coag-
ulation are associated with abnormal placental develop-
ment which may lead to inadequate fetomaternal
circulation and decreased placental perfusion [22]. In nor-
mal pregnancy the trophoblast invades the spiral arteries
which lose their muscular wall and become flaccid allow-
ing maximum blood flow to the placenta. The abnormal
interaction between mother and fetal allograft in abnor-
mal pregnancies leads to abnormal trophoblastic invasion
of the spiral arteries, resulting in small narrowed vessels.
The subsequent vasculopathy and secondary thrombosis
from hypercoagulability may result in inadequate per-
fusion of the intervillous space, preeclampsia, placental
infarcts, IUGR, placental abruption and IUFD. Placental
pathologists use the term placental vasculopathy to
describe pathological placental changes characterized by
superficial endovascular cytotrophoblast invasion in the
spiral arteries, acute atherosis and thrombotic processes in
the spiral arteries and/or the intervillous space. Clinically,
placental vasculopathy is associated with preeclampsia,
IUGR, placental abruption and some cases of fetal loss
and preterm labor [22].
The known thrombotic nature of the placental vascular
lesions and the increased thrombotic risk associated with
the existence of thrombophilias strongly suggest a cause-
and-effect relationship between inherited and acquired
thrombophilias and the listed severe obstetric
complications.
Placental findings associated with 
thrombophilias and pregnancy complications
The group from Tel-Aviv, [23] described placental find-
ings in women who had severe complications during
pregnancy and were carriers of thrombophilias, and com-
pared them to women with severe complications during
pregnancy but who had no thrombophilias [23]. Sixty
eight women with singleton pregnancies who had severe
preeclampsia, IUGR, abruptio placentae or IUFD com-
prised the study population. They were evaluated after
delivery for the occurrence of mutations of FV Leiden,
MTHFR, and prothrombin gene, and deficiencies of pro-
tein S, protein C and antithrombin. All were negative for
antiphospholipid antibodies. Thirty two women carried a
thrombophilia and 36 women did not. All placentas were
evaluated by a single pathologist who was blinded for the
results of thrombophilia assessment. There was no differ-
ence in the maternal age, parity, type of pregnancy com-
plication and fetoplacental weight ratio between the
groups. The number of women with villous infarcts was
significantly higher in women with thrombophilias (72%
vs. 39%, p < 0.01) as was the number of women with mul-
tiple infarcts, p < 0.05. The incidence of placentas with
fibrinoid necrosis of decidual vessels was also signifi-
cantly higher in women with thrombophilias (p < 0.05).
However, in a recent study with a very similar design and
which also examined the relationship between placental
histology and thrombophilia in women with severe com-
plications, no specific histological pattern could be iden-
tified when thrombophilia positive and thrombophilia
negative groups were compared [24]. Nevertheless, a high
rate of placental infracts (50%) and thrombosis was con-
firmed in both women with and without thrombophilias
[24]. Likewise, placental pathology in early onset preec-
lampsia and FGR was similar in women with and without
thrombophilia although a high rate of placental abnor-
malities was found [25]. Arias et al. [26], evaluated 13
women with thrombotic lesions of the placenta. All
women had obstetric complications such as preeclampsia,
preterm labor, IUGR or stillbirth. In 10 of 13 women
(77%) inherited thrombophilias were found; 7 were het-
erozygous for the FV Leiden mutation, and 3 had protein
S deficiency. The most prominent placental lesions were
fetal stem vessel thrombosis, infarcts, hypoplasia, spiral
artery thrombosis and perivillous fibrin deposition.
The high rate of placental lesions found in both throm-
bophilic women and non thrombophilic women with
severe complications in these studies may explain the dif-
ficulty to find a difference between thrombophilic and
non thrombophilic women, or may reflect an as yet
unknown state of thrombophilia. It should be noted how-
ever, that all these reports evaluated mixed clinical condi-
tions and not just severe preeclampsia.
Aquired thrombophilia
The antiphospholipid syndrome and pregnancy 
complications
The antiphospholipid syndrome (APS), an acquired
autoimmune condition, is characterized by the presence
of certain features and circulating antibodies. It is definedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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as the presence of lupus anticoagulant (LAC) and/or anti-
cardiolipin antibodies (aCL) with recurrent miscarriage
(RM), thrombosis, preeclampsia, IUGR and placental
abruption. The most specific clinical features are throm-
bosis (both venous and arterial thrombosis), RM and fetal
loss in the second and third trimester and autoimmune
thrombocytopenia [27-29].
The APS is associated with placental vascular thrombosis,
decidual vasculopathy, intervillous fibrin deposition, and
placental infarction [21,30]. These pathological changes
in the placenta may result in miscarriage, IUGR, stillbirth,
and early severe preeclampsia. In relation to fetal loss,
positive test for aCL or presence of LAC may be found in
up to 20% of women with recurrent pregnancy loss [31-
36]. It may present with either recurrent embryonic loss
[37], or fetal demise beyond 10 weeks of gestation [38]
and is found in 10–15% of women with fetal death
beyond 20 weeks of gestation [39,40]. The relation
between APS and preeclampsia has been shown in several
studies [40-46]. In a series of more than 300 patients with
severe preeclampsia, reported by the Amsterdam group
[44], an overall incidence of 21% was found related to
detectable ACA (> 10 GPL and/or MPL), with a 27.4%
incidence in the group with delivery at less than 28 weeks'
gestation, and a 19.3% incidence in the group with deliv-
ery more than 28 weeks' gestation. However, after consid-
ering the nearly 20% low positive IgG and/or IgM titers (<
15 GPL and/or MPL) in their control population of
healthy female volunteers, the authors concluded [43]
that 16% is a realistic estimate of the incidence of aCL pos-
itive patients in patients with a history of severe preec-
lampsia, which is concordant with other studies
[42,45,47]. It should be noted that several investigators
found no correlation between APS and preeclampsia [48-
50]. Since in early-onset severe preeclampsia most studies
found an association with positive tests for aCL, testing in
these patients may have therapeutic implications for
future pregnancies. Women with APS are also at a substan-
tial risk for IUGR [40,51,53] which is around 30%. In one
study, 24% of mothers delivered of IUGR infants had
medium or high positive tests for aCL [54].
Inherited thrombophilias and pregnancy 
complications severe preeclampsia and 
inherited thrombophilia
Dekker et al. [43], tested women with severe preeclampsia
at least 10 weeks post partum for the presence of inherited
and acquired thrombophilias. A high rate of protein S
deficiency, APCR, hyperhomocysteinemia and aCL IgG or
IgM was found. Dizon-Townson et al. [55] and Nagy et al.
[56] described a higher prevalence of FV Leiden mutation
in women with severe preeclampsia compared to controls.
In the study of Dizon-Townson et al [55], 158 nulliparous
women with severe preeclampsia at a mean gestational
age of 33 weeks were compared to 403 normotensive
women. Nagy et al. [56] in Hungary described a high prev-
alence of the FV Leiden mutation in 69 women with
severe preeclampsia compared to 71 healthy controls.
Rigo et al. [57] investigated 120 women with severe preec-
lampsia, (72% nulliparous) and 101 healthy matched for
age and parity. 18.3% of preeclamptic women were carri-
ers of the FV Leiden mutation compared to 3% in controls
(p < 0.001). However, there was no difference in homozy-
gosity for MTHFR. Among FV Leiden positives there was a
statistically higher prevalence of HELLP syndrome com-
pared to FV Leiden negatives. Perinatal outcomes were
comparable in FV Leiden positive and negative women.
Kupferminc et al. [47] conducted a study in order to deter-
mine whether obstetric complications are associated with
thrombophilias. 110 healthy women who had during
pregnancy severe preeclampsia, IUGR (<5th percentile),
severe abruptio placentae and stillbirth were enrolled in
the study. The control group comprised 110 healthy
matched women with normal pregnancies. All 220
patients were tested for all known thrombophilias at least
2 months after delivery. 34 out of 110 patients had severe
preeclampsia. All were nulliparous. The FV and MTHFR
mutations were significantly higher in women with preec-
lampsia (26% vs. 6.4% and 20.6% vs. 8.2%, respectively).
The prothrombin mutation was not more prevalent in
women with preeclampsia. Overall, 52.9% of patients
with severe preeclampsia had a genetic thrombophilic
mutation compared to 17.3% in the control group. In
additional 14.7% of the study group other types of throm-
bophilia were found. Thus, the total prevalence of throm-
bophilias in the women with preeclampsia was 64.7%
compared to 18% in controls. In women with IUGR,
abruptio placentae and stillbirth the thrombophilia rate
was 61.4%, 70% and 50%, respectively. The total preva-
lence of all thrombophilias detected in the 110 women
with complications was 65% compared to 18% in con-
trols. Of the 18 multiparous women in this group, 15 had
had obstetric complications in a previous pregnancy. In
10 of these 15 multiparous women (67%) thrombophilia
was found. This indicates a high rate of recurrence in mul-
tiparous women with thrombophilias. van Pampus et al.
[44], in Netherlands described 345 women with a history
of severe preeclampsia diagnosed before 34 weeks, who
were investigated postpartum for the presence of throm-
bophilias. The control group consisted of 67 healthy
women with a history of uncomplicated pregnancies.
The women with preeclampsia were further divided into
those who had delivered at less than or more than 28
weeks' gestation. In both sub-groups and in all women
study patients, a higher prevalence of APCR was found
compared to controls, but the prevalence of the FV Leiden
mutation was similar to controls. Hyperhomocysteinemia
was more prevalent in women with severe disease whoReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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had delivered at less than 28 weeks. Kupferminc et al. [58]
in another study tested 63 healthy women with severe
preeclampsia (54 nulliparous) and 126 matched controls
for all thrombophilias. Again, FV Leiden mutation and
MTHFR mutations were significantly more prevalent in
women with severe preeclampsia but not the pro-
thrombin mutation. Overall 56% of women with severe
preeclampsia had a genetic thrombophilic mutation com-
pared to 19% in the control group and the incidence of all
thrombophilias was 67% in severe preeclampsia. Women
with severe preeclampsia and thrombophilia delivered
earlier and the neonates were of lower birth weight com-
pared to preeclampsia and no thrombophilia (31 weeks
vs. 33 weeks). The incidence of combined thrombophilias
was also more prevalent in severe preeclampsia. Throm-
bophilia was found in four of the seven multiparous
women with preeclampsia (57%) who had had obstetric
complications in a previous pregnancy which indicates
high rate of recurrence in these women. Von Tempelhof et
al. [59] in Germany examined the FV Leiden mutation, PS,
PC, AT III, aCL and LAC in 61 women with severe preec-
lampsia (44 nulliparous) of whom 32 had HELLP syn-
drome. The FV Leiden mutation prevalence was higher in
both severe preeclampsia and HELLP as were also aCL or
LAC. Livingstone et al. [60], in USA tested the genetic
thrombophilic mutations in 110 women with severe
preeclampsia and 97 controls. Most women were nullipa-
rous and 60% of them were African Americans. No differ-
ence was found in the prevalence of thrombophilias
between the women with severe preeclampsia and control
women groups, or in fetal genetic thrombophilias. Lai-
vuori et al in Finland [61] tested 113 nulliparous women
with preeclampsia: 100 with severe disease, 13 with mild
disease and 103 controls for the C677T polymorphism of
the MTHFR gene. No difference in homozygosity for
MTHFR was found between the 2 groups (preeclampsia
3% vs controls 6%). Higgins et al. [62], tested the pro-
thrombin mutation in 13 eclamptic and 74 preeclamptic
women with severe disease coming from 34 families of
mostly Anglo-Saxon origin. They were compared to 119
controls. The prothrombin mutation was found in only
one family of the 34 tested and was similar in cases and
controls. Kupferminc et al. [63] tested for the pro-
thrombin mutation 222 patients with: severe preeclamp-
sia (n = 55), mild preeclampsia (n = 25), and other
complications and also 156 healthy women. Twenty eight
(13%) were heterozygotes of the prothrombin mutation
compared to 5 (3.2%) of the controls (p = 0.001). In
women with severe preeclampsia the prevalence of the
mutation was 9% compared to 3.2% in controls [p = 0.07,
OR 2.8 (0.9–9.4)]. Abruptio placentae and IUGR were sig-
nificantly associated with the mutation. Within the study
group, of the 9 multiparous carriers of the mutation, six
(66%) had had complications in previous pregnancies
compared to 27 out of 112 (24%) multiparous women in
the study group without the mutation p= 0.01. Krauss et
al., [64] in Germany, detected a higher incidence of APC
resistance in 21 women who had HELLP syndrome,6
months to 9 years after completion of pregnancy, com-
pared to normal values obtained from 70 healthy non
pregnant females.
Mild or unknown type of preeclampsia and 
inherited thrombophilia
Grandone et al. [65] in Italy, compared women with Ges-
tational hypertension (GH) to 129 healthy controls with
similar ethnic background. Forty five had preeclampsia
and 51 had non proteinuric hypertension. Seventy six per-
cent of women were nulliparous. The prevalence of FV Lei-
den mutation and C677T MTHFR mutations were
significantly higher in women with preeclampsia. In a
later study, Grandone et al. [66] investigated the preva-
lence of prothrombin mutation and FV Leiden mutation
in 140 women (62% nulliparous) with gestational hyper-
tension with (n = 70) or without proteinuria (n = 70) and
216 controls. The FV and prothrombin mutations preva-
lence were higher in women with hypertension compared
to controls while MTHFR mutation prevalence was similar
in preeclamptic and controls. In the 70 women with
preeclampsia the prothrombin and MTHFR mutations
were more prevalent compared to the controls but not the
FV Leiden mutation. Among non-proteinuric patients a
significant association with FV Leiden mutation was
found. O'Shaughnessy et al., [67] compared in a prospec-
tive study 283 women (230 primigravidas) with preec-
lampsia to 100 age-matched normal women and to
another 100 normotensive women. There was no differ-
ence in the frequency of FV Leiden mutation or MTHFR
mutations compared to the control group. A significant
increase in homozygosity for the C677T MTHFR mutation
in preeclampsia was reported by Shoda et al. in Japan [68]
who tested 67 women and 98 pregnant controls Lindoff et
al. [69], in Sweden compared 50 women with previous
preeclampsia to 50 controls and found that the APC ratios
were significantly lower in women with preeclampsia but
the difference in FV was not significant. Mello et al. [70],
in Italy, investigated the prevalence of thrombophilias in
46 nulliparous women with preeclampsia and in women
with a history of fetal loss in the second and third trimes-
ter. The frequency of APCR and FV Leiden mutation was
significantly higher in women with preeclampsia and in
the fetal loss group compared to the control group.
Lindqvist et al. [71], in a retrospective study investigated
the role of APCR and FV Leiden mutation in 2,480 women
enrolled in early pregnancy. The overall prevalence of APC
resistance was 11% (270/2480). The APC-resistant sub-
group (n = 270) did not differ significantly from the non-
APC-resistant subgroup (n = 2210) in terms of preeclamp-
sia or IUGR, but was characterized by an 8-fold risk of
venous thromboembolism. De Groot et al. [72] inReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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Netherlands in a retrospective study examined 163
women who had preeclampsia in their first pregnancy and
163 controls matched for age gravidity and date of deliv-
ery. The prevalence of FV Leiden mutation and pro-
thrombin mutations was similar in the groups. Morison et
al. [73] in Scotland in a retrospective study examined nul-
liparous women with preeclampsia or gestational hyper-
tension and healthy controls. They tested for genetic
thrombophilias and plasminogen activator inhibitor
(PAI-1) polymorphism. No difference was found in the
prevalence of thrombophilias between women with
preeclampsia, gestational hypertension and controls.
Murphy et al. [74] screened 584 primigravid subjects for
MTHFR and FV Leiden mutation mutations. 2.7% were
heterozygous for FV Leiden and 10.6% homozygote for
MTHFR mutation. The frequency of these polymorphisms
was not higher in those who subsequently developed
preeclampsia (n = 12) or IUGR (10th percentile) (n = 9).
Kim et al. [75] in a retrospective study in the USA, tested
white women with preeclampsia and controls for C677T
MTHFR and FV Leiden mutations and mutation of cys-
tathionine beta synthase. There was no difference in the
prevalence of these mutations either independently or in
combination in women with mild or severe preeclampsia
or HELLP syndrome. Among multiparous women with
preeclampsia the prevalence of MTHFR was 15.7% com-
pared to 10.9% among nulliparous with preeclampsia.
This may indicate that women with this mutation are at
high risk for developing recurrent preeclampsia [75].
Powers et al. [76], compared the prevalence of MTHFR
mutation between 99 nulliparous women with preec-
lampsia, 24 women with transient hypertension, 14 con-
trols and their infants. No differences were noted in the
mutation prevalence between women with preeclampsia
and controls or between infants of preeclamptic mothers
and controls. Lachmeijer et al. [77] in Netherlands studied
the MTHFR C677T and MTHFR A1298C mutations is
association with preeclampsia. One group consisted of 47
consecutive unrelated women with preeclampsia.
Another group included 127 unrelated women with
preeclampsia from affected sib-pair families and a control
group of 120 healthy women. Another 85 women with
preeclampsia and known homocysteine status were tested
for the relation between the C677T mutation and hyper-
homocysteinemia. Both MTHFR mutations were not
more frequent in women with preeclampsia. Women with
preeclampsia and hyperhomocysteinemia had a higher
prevalence of the C677T mutation compared to women
with preeclampsia but without hyperhomocysteinemia,
but not the A1298C mutation.
Zusterzeel et al. [78] from the Netherlands and Kaiser et
al. [79], in Australia also could not find a difference
between women with preeclampsia or HELLP syndrome
and controls in the prevalence of both these MTHFR
mutations, while Hauge et al. [80] found higher preva-
lence of homozygosity for the A1298C mutation in 64
women with severe preeclampsia and
hyperhomocysteinemia.
Several studies described higher levels of homocysteine in
preeclampsia. Rajkovic et al. [81], reported that homo-
cysteine levels were doubled in 20 women with preec-
lampsia compared to 20 healthy controls. Vollset, [82] In
the Hodarland homocysteine study which is the largest
performed to date, plasma homocysteine levels were eval-
uated in 5883 women with 14,492 pregnancies. It was
shown that when comparing the upper with the lower
quartile of plasma homocysteine, the adjusted risk for
preeclampsia was 1.32 (95% CI 0.98–1.77), for very low
birth weight 2.01 (95% CI 1.23–3.27), and for stillbirth
2.03 (95% CI 0.98–4.21). Cotter et al. [83] found that in
56 women who developed severe preeclampsia homo-
cysteine levels measured at 15.3 weeks were higher com-
pared to those obtained from 112 healthy controls with
normal pregnancy.
Inherited hypofibrinolytic mutations are also associated
with pregnancy complications. [84] Glueck et al. [85]
investigated the hypofibrinolytic 4G/4G mutation of PAI-
1 gene as a possible factor contributing to obstetric com-
plications. They compared women who had obstetric
complications including 31 with severe preeclampsia to
matched control women with normal pregnancies.
Women with obstetric complications were more likely
than controls to be 4G/4G homozygotes.
Recurrence rate of adverse pregnancy outcome
Several studies demonstrate a high recurrence rate in
women with severe preeclampsia/ HELLP syndrome. [86-
88] Several studies albeit small, showed that in multipa-
rous women with thrombophilias and severe pregnancy
complications there is high (66–83%) recurrence rate in
subsequent pregnancies, while the type of complication
may change from one pregnancy to the other; e.g. severe
preeclampsia to IUGR [47,58,59,63].
Summary: Preeclampsia and thrombophilia
The differences between reports may be related to differ-
ent populations studied, study design and different defini-
tions of preeclampsia. Some studies deal with mild
preeclampsia and other with severe disease. Several stud-
ies include only primigravidas and other both primigravi-
das and multiparous. Some include also women with
recurrent preeclampsia. The fetus may also play a role:
When the fetus has inherited thrombophilia from the
mother there may be an accelerated rate of thrombosis in
the placenta with ensuing complications compared to a
situation with a unaffected fetus. It is also possible that
other, as yet undefined genes need to be activated in orderReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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to induce thrombophilic states with clinical significance
in preeclampsia.
Since the rate of venous and arterial thrombosis and of
placental thrombosis in pregnancy complications is not
essentially different between ethnic groups and races, it
may be that other thrombophilias as yet unknown play a
role. For example, the FV Leiden mutation is highly prev-
alent among the Caucasian population, the prevalence
ranging from 10–15% in Sweden, 4–8% in central
Europe, and 2% in the south, and 5% in USA. The muta-
tion is almost non-existent in Asia, Japan, Africa and
South America. Preeclampsia is a multigenetic disease,
and there are important difference in prognosis and man-
agement between late mild preeclampsia and early onset
severe disease. Most studies and a recent meta analysis
[73] suggest that there is an association between throm-
bophilias and the development of severe preeclampsia
but not in mild preeclampsia [73]. The low-pressure inter-
villous blood flow in the presence of a maternal hyperco-
agulable state may trigger fibrin deposition in the placenta
and cause placental infarcts which may incite develop-
ment of early severe disease.
The evidence in the literature summarized also in a recent
meta-analysis [73] suggests that severe preeclampsia but
not mild preeclampsia is associated with trombophilias.
Mainly severe preeclampsia is associated with FV Leiden
mutation hyperhomocyteinemia, and deficiencies of pro-
tein S C and AT III (Table 1). It is not clear as yet, whether
severe preeclampsia is associated with the prothrombin
and MTHFR mutations.
Inherited thrombophilias and IUGR
Only few studies reported on an association between
IUGR and thrombophilias. de Vries et al. [89], studied
thrombophilias in 62 women with obstetric complica-
tions and compared the results to historical data. Thirty
one women had abruptio placentae, 18 had IUFD and 13
IUGR. Most prominent in women with IUGR was the
high incidence of hyperhomocysteinemia (38%), protein
S deficiency (23%) and FV Leiden mutation (12.5%).
Kupferminc et al. [47] investigated 110 women with
severe preeclampsia, IUGR below <5th percentile, severe
abruptio placentae and IUFD > 23 weeks. Forty-four
women had IUGR. The mean birth weight was 1387 ± 616
grams and 64% of patients delivered at less than 36 weeks,
with a mean gestational age of 33.2 ± 3.9. In 50% of the
women with severe IUGR a genetic thrombophilic muta-
tion was found. In additional 11.4% of women with
IUGR, other thrombophilias were found. Thus, the total
prevalence of thrombophilias in women with IUGR was
61.4%. The total prevalence of all thrombophilias in the
110 women with severe obstetric complications was 65%
compared to 18% in control women. The women with
obstetric complications had also significantly higher inci-
dence of combined thrombophilias. Kupferminc et al.
[63], in another study, tested the prothrombin mutation
in patients with severe preeclampsia (n = 55), mild preec-
lampsia (n = 25), IUGR defined as birtweight below the
10th percentile (n = 72), severe abruptio placentae (n =
27), unexplained stillbirth > 23 weeks' gestation (n = 16),
second trimester fetal loss, three or more consecutive first
trimester losses and 156 healthy control women who had
at least one normal pregnancy. Twenty-eight women of
the study group (13%) were found to be heterozygous car-
riers of the 20210 variant of the prothrombin gene com-
pared to five (3.2%) of the control group (p = 0.001, OR
2.9; 95% CI 1.3–6.5). Compared to controls, the pro-
thrombin gene mutation was significantly more prevalent
in women with IUGR, abruptio placentae, and second tri-
mester loss but not in women with mild or severe preec-
lampsia, stillbirth and habitual abortion. The 28 women
in the study group, carriers of the prothrombin mutation
had 62 pregnancies of which only 7 (11.3%) were nor-
mal. Within the study group, of the 9 multiparous
Table 1: Association of pregnancy complications and thrombophilias
Mild preeclampsia Severe preeclampsia IUGR Placental abruption
Antithrombin deficiency ++ ++ +
Protein S deficiency ++ ++ ++
Protein C deficiency ++ ++
APC resistance ++ ++ ++
Factor V Leiden ++ ++
MTHFR C677T +
Hyperhomocysteinemia ++ ++ ++
Factor II G 20210A + ++ ++
Antiphospholipid syndrome ++ ++ ++
Combined defects ++ ++ ++
Degree of association : + possible association; established association ++Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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patients carriers of the mutation, six (66%) had had com-
plications in previous pregnancies compared to 27 out of
112 (24%) multiparous women in the study group with-
out the mutation (p= 0.01). This again indicates a high
rate of recurrence in women with complications of preg-
nancy associated with thrombophilias.
Martinelli et al. [90], tested 63 women with history of
IUGR defined as birth-weight under the tenth percentile
and 93 parous women with uneventful pregnancies for
the mutations of FV Leiden and prothrombin gene. In 42
women IUGR was associated with gestational hyperten-
sion. Thirteen women were under the fifth percentile and
five under the third percentile. The women with IUGR
delivered at mean gestational age of 34.6 ± 3.4 weeks and
the mean birth weight was 1584 ± 586 grams. 95% were
delivered by cesarean section indicating high risk deliver-
ies. Among the women with IUGR 13% had the FV Leiden
mutation compared to 2.2% in the controls (OR 6.9,
95%CI 1.4–33.5), and 12% had the prothrombin muta-
tion compared to 2.2% in controls (OR 5.9, 95%CI 1.2–
29.4). Six women had combined thrombophilias. In
regression analysis model these thrombophilias were
again independently associated with IUGR. In a later
report from the same group [91], these mutations were
tested in neonates < 2500 grams. Three hundred ninety six
women with history of recurrent pregnancy losses or ges-
tational hypertension and 359 women with one or more
uneventful pregnancies were tested for these mutations.
Neonates delivered by mothers with thrombophilic muta-
tions comprised 30% of babies weighting < 1000 g, 18.7%
of those ranging from 1001–2499 g and 9.5% among
babies weighting ≥ 2500 g. Overall, 27.6% of neonates
delivered by of mothers with the mutations weighted less
than 2500 g compared to 13.9% neonates from mothers
without these mutations (OR 2.4, 95% CI 1.5–3.7). A
logistic regression analysis taking into account different
diagnoses, parity, twin birth showed again that carrier sta-
tus – of prothrombotic mutations was significantly associ-
ated with a birth-weight < 2500 g (OR 2, 95% CI 1.1–3.6).
Overall 22.8% of neonates under the 10th percentile were
from mothers with thrombophilic mutations compared
to 14.5% of neonates under the 10th percentile from
mothers without thrombophilic mutations (OR 1.7, 95%
CI 1.1–2.7). Recently, Infante-Rivard C et al. [92] did not
find an association between thrombophilic mutations
and IUGR < 10th percentile. In this study 493 newborns
with IUGR and 472 controls and their parents were tested
for thrombophilic mutations. The risk of IUGR was not
increased among mothers with thrombophilias. In addi-
tion these polymorphisms in the newborns were not asso-
ciated with an increased risk of IUGR. Several important
differences between this study and the previous studies
are apparent. In this study, the mean birth weight was
2393 ± 606.2 grams, and 83% of the patients delivered at
36–40 weeks' gestation. In the study of Kupferminc et al.
[47] the mean birth weight was 1387 ± 616 grams and the
mean gestational week was 33.2 ± 3.9. Similarly, Mar-
tinelli et al. [90], reported a mean gestational week at
delivery of 34.6 ± 3.4 and a mean birth weight of 1584 ±
586 grams. In the later study this group reported that
neonates from thrombophilic mothers formed 30% of
those weighting < 1000 grams [91]. It is known that IUGR
is associated with increased morbidity and mortality, both
antepartum and postpartum [90]. However, the use of the
10th percentile may include many constitutionally small
fetuses which carry none of the clinical risks of growth
restricted fetuses [90]. Conversely, the combination of
prematurity and IUGR carries a high risk of long-term seri-
ous sequelae [90]. It is evident from these differences in
birth weights and gestational age that these studies are
dealing with different fetal and neonatal populations with
different clinical relevance. In the Hodarland homo-
cysteine study [82], plasma homocysteine levels were
evaluated in 5883 women with 14,492 pregnancies. It was
shown that when comparing the upper with the lower
quartile of plasma homocysteine, the adjusted risk for
preeclampsia was 1. 32 (95% CI 0.98–1.77), for prematu-
rity 1.38 (95% CI 1.09–1.75), for very low birth weight
2.01 (95% CI 1.23–3.27), and for stillbirth 2.03 (95% CI
0.98–4.21). Placental abruption had no correlation with
the homocysteine quartile, but the adjusted OR when
homocysteine concentrations >15 µmol/L were compared
with lower values was 3.13 (95% CI 1.63–6.03).
Kupferminc et al. [94] tested a very selective group with
severe midtrimester IUGR (22–26 weeks' gestation)
defined as birth weight <3rd percentile and associated with
oligohydramions (n = 26). The frequency of throm-
bophilias was 69% in the study group compared to 14%
in the control group (n = 56) [odds ratio (OR) 4.5; 95%
confidence interval (CI) 2.3–9, P < 0.001]. The frequen-
cies of FV Leiden mutation, prothrombin gene mutation
and protein S deficiency were significantly increased in
the study group compared to the control group. The fre-
quency of multiple thrombophilias was 33% in the study
group versus none among the controls. Of the 26 preg-
nancies with severe mid-trimester IUGR, 13 ended in
IUFD before 25 weeks' gestation: 10 of these women had
thrombophilia. Table 1 summarizes the association
between individual thrombophilias and IUGR.
Inherited thrombophilias and abruptio 
placentae
Van der Molen et al. investigated coagulation inhibitors
and abnormalities of the homocysteine metabolism as
risk factors for placental vasculopathy [95]. They
compared non-pregnant women with a history of placen-
tal vasculopathy defined as abruption or placental infarc-
tion with non-pregnant women matched for age andReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
Page 8 of 22
(page number not for citation purposes)
occupation. Placental infarction was defined as villous
necrosis associated with a stillborn baby or IUGR at less
than the 10th percentile. Twenty-two of 101 had also
hypertension during pregnancy. Protein C activity was sig-
nificantly lower. Homozygotes for the MTHFR mutation
and carriers of the FV Leiden mutation were significantly
more frequent in the study group. The median homo-
cysteine levels, APCR ratio, protein S and AT-III were not
different between the groups. However, a significant OR
for homocysteine was found above 14.4 micromole
which was the 80th percentile of the controls. Also, combi-
nation of risk factors such as homocysteine levels above
14.4 micromol and protein S deficiency resulted in a sig-
nificant increased OR. So that the risk factors for placental
vasculopathy which emerge in this study are decreased
levels of APCR and protein C, elevated homocysteine and
the MTHFR mutation or combinations of these.
Wiener-Megnagi et al. [96], studied 27 women who had
abruptio placentae and 29 control subjects matched for
age, parity, and ethnic origin. Sixty three % of case
patients had an activated protein C ratio ≤ 2.5, compared
with 17% of control subjects with an OR of 8.16 (p
=.00125). Only participants with APCR ≤ 2.5 underwent
DNA analysis. Eight of 15 case patients tested were found
to have the FV Leiden mutation (5 heterozygous and 3
homozygous, 29.6%), compared with 1 heterozygote
among the control subjects who were tested (3.4%).
Goddjin-Wessel et al. [97] found hyperhomocysteinemia
in 31% of women with abruption or infarction compared
to 9% in controls (p < 0.05). Kupferminc et al. [47] found
a 70% incidence of thrombophilias in women with
abruptio placentae. Sixty percent of these had throm-
bophilic mutations and 10% had AT-III deficiency or APS.
Twenty women had abruptio placentae, among whom
three also had mild preeclampsia, seven had antepartum
or postpartum hypertension, and eleven of the neonates
were below the 10th percentile for gestational age. In this
study, which was the first to examine the prothrombin
mutation in women with pregnancy complications, the
OR for this mutation was 8.9; 95% CI 1.8–43.6, whereas
the OR for FV Leiden mutation were 4.9; CI 1.-17.4, and
for MTHFR mutation the OR was 2; CI 0.5–8.1. In another
study [63], the rate of the prothrombin mutation in 27
women with abruptio placentae was 18.5% compared to
3.2% in controls (OR 5.8; 95% CI 1.8–18.6), P = 0.01. In
the study of de Vries et al. [89] abruptio placentae was
associated with 26% hyperhomocysteinemia and 29%
protein S deficiency. Table 1 summarizes the association
between individual thrombophilias and abruptio
placentae.
Inherited thrombophilias and fetal loss
About 15% of all pregnancies will terminate in miscar-
riage. Recurrent miscarriage (RM) is a condition defined
as three consecutive miscarriages and affects 1%-2% of
women of reproductive age. Up to 5% have ≥ 2 recurrent
losses. These sporadic miscarriages are the commonest
complication of pregnancy and are mainly due to chro-
mosomal abnormalities in the fetus.
It is now widely accepted that RM is a heterogeneous con-
dition, with several etiological factors such as prothrom-
bolic states, structural uterine anomalies, chromosomal
anomalies, and endocrinological defects. In up to 80%,
however, the underlying cause is not apparent and the
condition is therefore considered unexplained.
Pregnancy is a hypercoagulable state, and women with
thrombophilia are at increased risk for thrombosis during
pregnancy and adverse maternal and fetal sequelae [98].
The hemostatic system plays an important role in the suc-
cess of pregnancy and the process of implantation, and
placentation. Implantation of the fertilized egg into the
uterine decidua establishes a contact between the fetus,
the placenta and the maternal circulation. This contact
between placenta and maternal circulation is crucial for
the success of pregnancy. Pro-thrombotic changes and
thrombosis may interfere with these processes leading to
miscarriage. This may explain many cases of previously
unexplained RM. In support of the role of thrombophilia
in RM are direct and indirect evidences.
Indirect evidence: Many women with a history of RM are
at greater risk of preeclampsia, IUGR and intra-uterine
fetal death, which suggests that these adverse pregnancy
outcomes represent a spectrum of disorders which share a
common origin [98]. Women with a history of RM are in
a prothrombotic state while not pregnant [98-102].
Thrombin antithrombin (TAT) complex levels are signifi-
cantly higher in women with both first and second trimes-
ter fetal losses compared to controls. It has also been
reported that women with RM are in a chronic state of
endothelial stimulation associated with activation of the
coagulation system [98]. Women with a history of RM
have an excess of thromboxane production at weeks 4–7
of gestation and between gestational weeks' 8 and 11 they
are relatively prostacyclin deficient compared with
women with no previous history of pregnancy loss [99].
These changes were greatest among those whose preg-
nancy ended in miscarriage. The shift in the thrombox-
ane/prostacyclin ratio in favor of the prothrombotic agent
thromboxane may lead to vasospasm and platelet aggre-
gation in the trophoblast, causing the development of
microthrombi and placental necrosis [98].
Direct evidence comes from studies finding higher preva-
lence of thrombophilias in women with RM. The results
vary between studies reflecting the fact that most studies
have included small numbers of women, have been proneReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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to selection bias and frequently failed to differentiate
between women with recurrent first trimester miscarriage
and those with later pregnancy complications.
Prospective studies [98] have demonstrated an increased
prevalence of antiphospholipid antibodies (aPL) among
women with first trimester RM. Some 15% of women with
RM have persistently positive tests for aPL. Several studies
have reported that the early fetal loss rate in women with
aPL is in the range of 50–70% [100-104]. The majority of
miscarriages amongst aPL-positive women occurred in the
first trimester of pregnancy after the establishment of fetal
heart activity. The outcome of pregnancy in untreated
women with a history of RM in association with APS is
poor with a live birth rate of about 20% whereas treat-
ment with antithrombotic therapy, such as aspirin and
heparin or low molecular weight heparin started early in
the first trimester of pregnancy has been shown to signifi-
cantly improve the live birth rate [98,103,104].
Prevalence of inherited thrombophilias in first 
and second trimester miscarriage
Studies reporting the prevalence of FV Leiden mutation
among women with RM cite figures ranging from 3 to
42%. Of all inherited thrombophilias many reports find
an association between high prevalence of the FV Leiden
mutation and RM. Brenner et al [105]. tested women with
3 or more first trimester losses, 2 or more second trimester
losses or one or more third trimester loss. The FV Leiden
mutation was more frequent in the fetal loss group com-
pared to controls. Thrombophilias were more common in
second and third trimester losses but first trimester recur-
rent abortion was not associated with thrombophilia. The
MTHFR or prothrombin mutations were not more com-
mon in women with fetal loss. Overall, 49% of women
with pregnancy loss had a thrombophilia compared to
22% of controls. Brenner et al. [106], analyzed 39 consec-
utive women with recurrent fetal loss of unknown cause
for activated protein C resistance, FV Leiden mutation, or
APCR without FV Leiden mutation. Evaluation of 128
pregnancies in 19 patients with FV Leiden mutation and
56 gestations in nine women with acquired APCr,
revealed over 50% first-trimester abortions and 17% late
abortions. Ridker et al [107], compared the frequency of
FV Leiden mutation in 113 women with recurrent fetal
loss to 437 controls. The mutation was found in 8% in
women with RM and in 3.7% of controls OR 2.3, 95%
CI,1.0–5.2. In a subgroup of patients with 3 or more preg-
nancy losses and no successful pregnancies, the preva-
lence of the mutation was 9% OR 2.6, 95% CI, 1–6.7.
Younis et al [108]. evaluated APCR and the FV Leiden
mutation in women with first trimester recurrent embry-
onic loss, in women with second trimester loss and con-
trols. The prevalence of APCR and FV Leiden mutation
was significantly higher in women with first and second
trimester recurrent pregnancy loss compared to the con-
trol group. Sarig et al. [109], evaluated 145 patients with
RM and 145 matched controls. At least one throm-
bophilic defect was found in 66% of study group patients
compared with 28% in controls. Combined throm-
bophilic defects were documented in 21% of women with
pregnancy loss compared with 5.5% of control patients.
Late pregnancy wastage occurred more frequently in
women with thrombophilia compared with women with-
out thrombophilia. The FV Leiden mutation was more
common in women with pregnancy loss but not factor II
G20210A and homozygosity for MTHFR. Tal et al. [110]
studied prospectively 125 patients with one or more first
or second trimester pregnancy losses and matched con-
trols for the prevalence of APCR. Pregnancy losses were
divided into preclinical, first trimester clinical and second
trimester abortion. The FV Leiden mutation was found in
14.4% of patients compared with 5. 6% in controls (P <
0.05). The rate of preclinical pregnancy losses in Leiden
mutation carriers was significantly higher compared to no
APCR patients. Finan et al. [111], tested 110 women with
Table 2: Association of fetal loss and thrombophilias
Early recurrent miscarriage (< 12–13 weeks) Late fetal loss
Antithrombin deficiency
Protein S deficiency ++ ++
Protein C deficiency
APC resistance ++
Factor V Leiden ++ ++
MTHFR C677T
Hyperhomocysteinemia ++ ++
Factor II G 20210A ++ ++
Antiphospholipid syndrome ++ ++
Combined thrombophilias ++ ++
Degree of association : established association ++Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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first trimester unexplained losses (≥ 2) and 67 controls.
Forty one % were carriers of the FV Leiden mutation com-
pared to 16.4% in controls, (p = 0.002). 13.6% were car-
riers of the prothrombin mutation compared to 3% in
controls (p = 0.001). Foka et al. [112] tested 80 women
with recurrent (≥ 2) losses and 100 controls. Sixty one out
of the 70 had first trimester losses. The prevalence of the
FV Leiden mutation was significantly higher in the
women with RM (19% vs. 4%, p = 0.003). The prevalence
of the prothrombin mutation was also significantly higher
in the study group (9% vs. 2%, p = 0,038). The MTHFR
mutation prevalence was similar between the groups.
Reznikoff-Etievan et al. [113] investigated 260 women
with 2 or more losses before 10 weeks of pregnancy and
240 controls. The FV Leiden mutation and G20210A
mutations were found to be associated with early recur-
rent spontaneous miscarriage before 10 weeks of preg-
nancy, the OR being 2.4 (95% CI 1–5) and 2.7 (95% CI
1–7), respectively. Similar results were found whether or
not women had had a previous live birth. Alonso et al.
[114] recently investigated inherited and acquired throm-
bophilia in women with unexplained abortions ≥ 1 first
trimester abortion after exclusion of abnormal karyotype
and other causes of abortions, and intrauterine fetal
death. Late fetal loss was associated with thrombophilia
but not early abortions. Other studies did not find an
association between the FV Leiden mutation and RM. Rai
et al. [115], investigated 1111 consecutive Caucasian
women with a history of either recurrent early miscarriage
(three or more consecutive pregnancy losses at <12 weeks
gestation; n = 904) or a history of at least one late miscar-
riage. A control group of 150 parous Caucasian women
with no previous history of adverse pregnancy outcome
was also studied. Acquired APCR was significantly more
common among both women with recurrent early miscar-
riage (8.8% vs. 3.3%; P = 0.02) and those with late miscar-
riage (8.7% vs. 3.3%; P = 0.04) compared with controls
(3.3%: 5/150). In contrast, the frequency of the FV Leiden
mutation allele was similar among women with recurrent
early miscarriage (3.3%) those with late miscarriage
(3.9%) and the control group (4.0%). Grandone et al.
[116] investigated the FV Leiden mutation in 43 women
with 2 or more unexplained fetal losses and 118 controls.
The mutation was more frequent in women with fetal
loss. The FV Leiden mutation was more frequent in
women with second trimester loss, but the prevalence of
the mutation in women with first trimester loss and con-
trols was similar. Kutteh et al. [117] tested 50 women with
recurrent pregnancy loss based on well-documented his-
tory. 189 pregnancies were before completion of week 12.
The prevalence of the genetic thrombophilias was similar
in the study and control group. Dizon-Townson et al. also
did not find an association between RM and the FV Leiden
mutation [118]. Studies regarding the association of
MTHFR and recurrent pregnancy loss are contradicting
with some who negate an association between MTHFR
and recurrent abortions [105,119], and others who find
such association [120,121].
Nelen et al. [122] performed a meta analysis to evaluate
the relation between recurrent early pregnancy loss and
hyperhomocyteinemia. In the papers included was their
own data. Evaluated were fasting or afterload homo-
cysteine concentrations and the MTHFR C677T mutation.
Overall, the pooled OR for elevated homocysteine were
2.7 (1.5–5.2), for afterload homocysteine 4.2 (2.0–8.8)
and for MTHFR 1.4 (1.0–2.0). These data support hyper-
homocysteinemia as a risk factor for recurrent early preg-
nancy loss. Homozygosity for the MTHFR mutation
represents a small increase in women's risk for recurrent
pregnancy loss. Some studies do not find an association
between the prothrombin mutation and RM [123-125],
while other studies do [111,112]. In addition, Pihusch et
al. [126] studied 102 patients with two or more consecu-
tive abortions and 128 women without miscarriage. No
differences in the prevalence of FV Leiden mutation,
MTHFR mutation or glycoprotein IIIa, and beta-fibrino-
gen polymorphism was found. The prothrombin muta-
tion occurred more often in patients with RM. This effect
was significant in 75 women with abortions exclusively in
the first trimester (6.7%, vs. 0.8%, P = 0.027, OR 8.5).
Sanson et al. [127], investigated women with deficiencies
of antithrombin, protein S and protein C. In the 60 defi-
cient subjects 22.3% of the 188 pregnancies resulted in
miscarriage or stillbirth as compared to 11.4% of the 202
pregnancies in the 69 non-deficient subjects. The relative
risk of abortion and stillbirth per pregnancy for deficient
women as compared to non-deficient women was 2.0
(95% C.I. 1.2–3.3). Women with dysfibrinogemia are also
candidates for miscarriage and of 64 pregnancies in
women with dysfibrinogemia 39% ended by miscarriage
[128].
Late fetal loss and thrombophilia
Preston et al. [129], reported on the relation between her-
itable thrombophilic defects and fetal loss in a cohort of
women with FV Leiden mutation or deficiency of anti-
thrombin, protein C, or protein S. The authors studied
1384 women enrolled in the European Prospective
Cohort on Thrombophilia (EPCOT). Of 843 women with
thrombophilia 571 had 1524 pregnancies; of 541 control
women 395 had 1019 pregnancies. The controls were
partners of male members of the EPCOT cohort or
acquaintances of cases. They analyzed the frequencies of
miscarriage (fetal loss at or before 28 weeks of gestation)
and stillbirth (fetal loss after 28 weeks of gestation) jointly
and separately. The risk of fetal loss was increased in
women with thrombophilia (OR 1.35 [95% CI 1.01–
1.82]). The OR was higher for stillbirth than for miscar-
riage (3.6 [1.4–9.4] vs. 1.27 [0.94–1.71]). The highest ORReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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for stillbirth was in women with combined defects (14.3
[2.4–86.0]) compared with 5.2 (1.5–18.1), in anti-
thrombin deficiency, 2.3 (0.6–8.3) in protein-C defi-
ciency, 3.3 (1.0–11.3) in protein-S deficiency, and 2.0
(0.5–7.7) with FV Leiden mutation.
The authors concluded that women with familial throm-
bophilia, especially those with combined defects or anti-
thrombin deficiency, have an increased risk of fetal loss.
Gris et al. [130], performed a case-control study in 232
women with a history of one or more second or third tri-
mester losses but no thrombosis who were matched with
464 controls and tested for thrombophilia and APS. They
found at least one thrombophilia in 21.1% of the patients
and in 3.9% of the controls (p < 10(-4)). In women, the
crude OR for stillbirth associated with any positive throm-
bophilia was 5.5, 95% CI [3.4–9.0]. Using conditional
logistic regression analysis, 4 adjusted risk factors for still-
birth remained: protein S deficiency, positive anti-beta2
glycoprotein IgG antibodies, positive aCL IgG antibodies
and the FV Leiden mutation. The C677T mutation in the
MTHFR gene was not an individual risk factor but an
homozygous genotype was strongly associated with the
former 4 risk factors (16.8% of patients vs. 0.9% of con-
trols). In women with such associations, stillbirths always
occurred in absence of folic acid supplementation during
pregnancy. Available conclusions of pathological analysis
of placentas were found to have a very high proportion of
"maternal vascular disease of the placenta" in patients
with at least one positive risk marker for
thromboembolism, specially in case of association with
the C677T MTHFR homozygous genotype, compared to
patients with negative markers (p < 10(-4)). The conclu-
sion was that late fetal loss, through placenta thrombosis,
might sometimes be the consequence of a maternal mul-
tifactorial prothrombotic state.
Kupferminc et al. [47] found a 50% prevalence of Throm-
bophilias in women with IUFD more than 23 weeks. Mar-
tinelli et al. [131], in a recent study studied 67 women
with fetal loss after the 20 weeks of pregnancy and 232
controls. 16% of the 67 women with fetal loss and 6% of
the controls had either the FV Leiden mutation or the pro-
thrombin mutations. The relative risks of late fetal loss in
carriers of the FV and prothrombin mutations were 3.2
(95% CI, 1.0–10.9), and 3.3 (95% CI, 1.1–10.3), respec-
tively. Placental pathology found histological evidence of
thrombosis in 76% of examined placentas examined.
Another study performed by the Tel-Aviv group, investi-
gated women with IUFD at 27 weeks' gestation or more
[132]. In 40 women with unexplained IUFD, the preva-
lence of inherited thrombophilias was 42.5% in the study
group compared with 15% in controls (OR 2.8, 95% con-
fidence interval 1.5, 5.3, P =.001).
Summary: fetal loss and thrombophilias
A recent meta-analysis [133] included 31 studies regard-
ing thrombophilic disorders and fetal loss. Factor V Lei-
den was associated with early and late recurrent fetal loss,
and late non-recurrent fetal loss. Activated protein C
resistance was associated with early recurrent fetal loss,
and prothrombin G20210A mutation with early recurrent
and late non-recurrent fetal loss. Protein S deficiency was
associated with recurrent fetal loss and late non-recurrent
fetal loss. Methylenetetrahydrofolate mutation, protein C,
and antithrombin deficiencies were not significantly asso-
ciated with fetal loss [133]. Table 2 summarize the
association between fetal loss and thrombophilias.
Management of fetal loss associated with 
thrombophilia
Recently, two prospective randomized studies have
shown that treatment with heparin plus low dose aspirin
results in significantly better gestational outcome that low
dose aspirin alone in women with APS syndrome who
experienced recurrent pregnancy loss (RPL) [100-104]. In
the study by Kutteh et al. [100], viable infants were deliv-
ered in only 44% of women receiving aspirin compared to
80% in women receiving also heparin (p < 0.05). The
study of Rai et al. [104], was a randomized controlled trial
of aspirin and aspirin plus heparin in pregnant women
with RM associated with antiphospholipid antibodies.
The rate of live birth in patients treated with aspirin and
heparin was 71% compared to 42% with aspirin alone (p
< 0.01). Still, 25% of successful pregnancies were deliv-
ered prematurely. Treatment consisted of prophylactic
heparin (5,000 IU b.i.d.), or LMW heparin, and low-dose
aspirin (0.1 g per day). The data for inherited throm-
bophilias is even more limited and no controlled trials
exists. Brenner et al. [134], evaluated 149 women with
recurrent first trimester abortion, two or more second tri-
mester abortions or IUFD. There were 254 pregnancies
with 67% pregnancy loss. They were evaluated for throm-
bophilia which was found in 50. Twenty three had a single
defect with FV Leiden mutation most common and 27
had combined thrombophilia. These 50 women had only
20% live births. The women with thrombophilia were
treated during pregnancy with Enoxaparin; 40 mg/day in
women with solitary thrombophilia and 80 mg/day in
women with combined thrombophilias in addition to
aspirin in women with APS. 45 of 61 (75%) gestations
treated by Enoxaparin resulted in live birth compared to
only 38/193 (20%) of the untreated pregnancies in these
50 women prior to diagnosis of thrombophilia (p <
0.00001). In 23 women without a single living child
following 82 untreated gestations, antithrombotic ther-
apy resulted in 26/31 (84%) successful deliveries (p <
0.0001). Younis et al. [135], measured activated protein C
(APC) resistance and FV Leiden mutation in 56 non-preg-
nant women, with a history of two or more unexplainedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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recurrent pregnancy losses. During the same study period,
seven women carrying the FV Leiden mutation conceived
and were subsequently followed throughout their
pregnancy.
Subcutaneous LMW heparin, (Enoxaparin, 40 mg/day)
and oral low dose aspirin (100 mg/day) were adminis-
tered throughout the pregnancies, starting at early first tri-
mester. Five of the seven pregnancies occurring progressed
uneventfully to term with normal fetal growth, normal
doppler flow studies and uneventful neonatal outcome.
Two of the seven women had early missed abortions.
Management of adverese pregnancy outcome 
associated with thrombophilia
Although at the moment our knowledge as for the opti-
mal treatment during pregnancy is limited, the data sug-
gest that certain risk groups such as pregnant women with
a personal or family history of thromboembolism should
be screened for thrombophilia. Testing should be also
performed to women with a history of recurrent first tri-
mester loss, second trimester loss, IUFD, severe preec-
lampsia, IUGR or abruptio placentae. Are women with
pregnancy complications and/or placental thrombosis
and thrombophilias candidates for anti-thrombotic ther-
apy as certainly are those with venous and arterial throm-
bosis? There are no controlled trials as to guide us how to
manage women with thrombophilia and previous placen-
tal thrombosis and/or severe pregnancy complications.
However, some data suggest a high recurrence rate of com-
plications in future pregnancies in women who had previ-
ously severe pregnancy complications and women with
severe complications who are carriers of thrombophilias.
Recently, the Cochrane Collaboration [136] reported a
15% reduction in the risk of preeclampsia (32 trials with
29,331 women; relative risk (RR) 0.85; 95% CI 0.78–
0.92) and a 14% reduction in fetal and/or neonatal death
(30 trials with 30,093 women; RR 0.86 95% CI 0.75–
0.99). This reduction in death was the greatest amongst
high-risk women (4134 women; RR 0.73 95% CI 0.56–
0.96). The combination of aspirin and heparin or low
molecular weight (LMW) heparin is effective in recurrent
fetal loss in APS syndrome and could be considered for
women with inherited thrombophilias and history of
severe preeclampsia, IUGR, abruptio placentae or fetal
loss, although no controlled studies on the subject are cur-
rently available.
An interest in the potential therapeutic value of heparin to
prevent and treat pregnancy complications has existed for
many years. One of the larger retrospective cohort studies
was performed by North et al. [137] who reported on
women with renal disease in pregnancy divided into a
control group, patients treated by low-dose aspirin, and
women reciving prophylactic heparin combined with
aspirin and/or dipyridamole. Preeclampsia was less com-
mon in the heparin group compared with the no-treat-
ment group and the aspirin group. Kupferminc et al.
[138], reported on the use of LMW heparin in prevention
of recurrent adverse pregnancy outcome. Women with a
history of severe preeclampsia, abruptio placentae, IUGR
or stillbirth and a known thrombophilia (n = 33) were
treated with Enoxaparin 40 mg/day and 100 mg aspirin
beginning from 8–12 weeks' gestation. The mean gesta-
tional age at delivery in the index pregnancies was 32.1 ±
5.0 weeks as compared to 37.6 ± 2.3 weeks' gestation in
the ensuing pregnancies treated with LMW heparin (P <
.0001). The mean birth-weight of the infants in the index
pregnancies was 1175 ± 590 g compared to 2719 ± 526 g
in the treated pregnancies (P < .0001). Pregnancy compli-
cations occurred in only three (9.1%) of the women and
severe preeclampsia did not occur in the treated pregnan-
cies. There were no perinatal deaths in the treated preg-
nancies. Ryazi et al. [139] evaluated treatment with LMW
heparin combined with aspirin in pregnant women with
thrombophilia and a history of early-onset preeclampsia
and/or IUGR. Twenty-six patients with thrombophilias
had a subsequent pregnancy and were treated with LMW
heparin plus aspirin. Their pregnancy outcome was com-
pared with all patients having a subsequent pregnancy
without thrombophilias receiving only aspirin (n = 19).
There was no difference in the overall birth-weight
between the groups. However, when considering the 18
patients with single coagulation abnormalities (i.e.
excluding 8 patients with multiple thrombophilias), birth
weights were significantly higher (p = 0.019) compared to
the 19 with no abnormality. In addition, two perinatal
deaths occurred in the aspirin group versus no perinatal
death in the aspirin plus LMW heparin group. These pre-
liminary studies suggest that LMW heparin may have an
additional favorable effect on pregnancy outcome of
women with a history of severe preeclampsia and/or
IUGR and documented thrombophilia. Large randomized
controlled are urgently needed.
Venous thromboembolism (VTE) in pregnancy
The risk of VTE in pregnancy is approximately six times
greater than in non-pregnant women and is a major cause
of death among women during pregnancy and the puer-
perium. Pulmonary embolism occurs in approximately 16
percent of patients with untreated deep vein thrombosis
(DVT), and is the most common cause of maternal death
[140-146]. The overall risk of DVT in pregnancy (0.05–1.8
percent) [144] is higher in women with a previous history
of VTE, with a recurrence rate of about 1 in 71 women
[147]. Maternal DVT is more common in the left leg
(accounting for about 85 percent of leg thrombosis),
occurs more commonly in iliofemoral veins than in calf
veins (72 percent compared with 9 percent, respectively),Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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and is more often associated with pulmonary embolism
(PE) [148].
Underlying factors increasing the risk of VTE in pregnant
women include obstruction of venous return by the
enlarging uterus, venous atonia [149] and the acquired
prothrombotic changes that occur in hemostatic factors.
The physiologic changes in the hemostatic system include
elevation of fibrinogen and FVIII, acquired functional
resistance to activated protein C, a decrease in protein S
and increases in plasminogen activator inhibitors 1 and 2
that decrease fibrinolysis and platelet activation
[140,145,150,151]. Advanced maternal age, obesity,
immobilization and the presence of maternal throm-
bophilias are additional factors. All these contribute to the
hypercoagulable state which occurs in a normal preg-
nancy. The incidence of clinical DVT is estimated at 0.08–
1.2 percent following vaginal delivery, rising to 2.2–3.0
percent following cesarean section [152]. Emergency
cesarean section is associated with the highest risk, and
maternal age and weight are also important predictive fac-
tors [153]. A high proportion of both post-partum DVT
and pulmonary embolism manifests after discharge from
hospital [154], highlighting the need for careful surveil-
lance in the puerperium [155].
If venous thrombosis is suspected during pregnancy, an
objective diagnosis must be obtained. With proper pre-
cautions, the radiation dose from the necessary investiga-
tions is small, and the risk to the fetus is negligible [154].
If VTE is suspected but unconfirmed by test results, treat-
ment should be started and tests repeated within 7 days;
therapy is discontinued if findings remain negative [146].
Pulmonary embolism usually occurs during the third tri-
mester or the post-partum period. Diagnosis during preg-
nancy is difficult as many of the signs and symptoms also
occur in healthy pregnant women, and pulmonary emboli
often arise from the pelvic veins while the leg veins remain
normal [152]. The elevation of D-dimers during preg-
nancy may be unrelated to VTE [151]. In many cases anti-
coagulant therapy should be initiated on the basis of
clinical awareness and suspicion only, but in view of the
potential hazards, an objective diagnosis is mandatory.
Hereditary thrombophilias and venous 
thrombosis during pregnancy
The risk of venous thrombosis in women with an inher-
ited or acquired thrombophilia is increased in pregnancy.
However, not all women with thrombophilia will develop
VTE during pregnancy, suggesting the existence of addi-
tional, yet unidentified, environmental factors. The risk of
VTE depends on the type of thrombophilia and the exist-
ence of additional risk factors.
AT III deficiency is the most thrombogenic of the heredi-
tary thrombophilias, with a 50 percent life chance of
thrombosis [155]. The frequency of ATIII deficiency in the
general population is 0.02–0.17 percent and is higher in
patients with VTE (1.1 percent). The risk of thromboem-
bolism in AT III deficient pregnant women not receiving
anticoagulant therapy is about 50 percent [156].
Abnormalities of the protein C and protein S system are
present in 0.14-0.5 percent of the general population and
3.2 percent of patients with thrombosis. The risk of
thrombosis in pregnancy is 3–10 percent for protein C
deficiency and 0–6 percent for protein S deficiency, sub-
stantially lower than for antithrombin-deficient women.
In postpartum women, the thrombosis risk is 7–19 per-
cent for protein C deficiency and 7–22 percent for protein
S deficiency [140,157,158].(While antigenic and func-
tional assays of protein C levels during pregnancy remain
unchanged, there is a marked decrease in protein S levels
(free protein S). Protein S levels are frequently abnormal
in pregnancy, in 25 percent of healthy women in the first
trimester, 60 percent in the second and 83–100 percent in
the third trimester [150]. Hence, when protein S defi-
ciency may be suspected during pregnancy, reliable assay
results are obtainable only in the first months of preg-
nancy. An alternative approach is to test the parents of the
patient.
Activated protein C resistance (APCR) is present in 3–7
percent of healthy Caucasians and in 20–30 percent of
patients with thrombosis. APCR has been found in up to
78 percent of women investigated for venous thrombosis
in pregnancy [160], whereas the FV Leiden mutation was
found in up to 46 percent of cases [143].
Recently, Gerhardt et al. described the prevalence of con-
genital thrombophilia in 352 women, 119 of whom had
a VTE during, or immediately after pregnancy [142]. In
women with VTE, the prevalence of FV Leiden mutation
was 43.7 percent, compared with 7.7 percent among the
age-matched normal women (RR 9.3; 95% CI, 5.1 to
16.9). The prevalence of the prothrombin-gene mutation
was 16.9 percent in women with VTE as compared with
1.3 percent in the control group (RR 15.2; 95% CI, 4.2 to
52.6). The prevalence of the combined defects of both FV
Leiden and prothrombin-gene mutation was 9.3 percent,
as compared with zero in the control group. The presence
of both mutations substantially increased the risk, with an
OR estimated at 107 for the combination of mutations.
Additional risk factors, such as AT III deficiency or protein
C and protein S deficiencies were present in 25 percent of
women with a history of VTE, as compared with 11 per-
cent of women with no history. In this study it was dem-
onstrated that the prothrombin-gene mutation and FV
Leiden mutation are individually associated with anReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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increased risk of VTE during pregnancy and the puerper-
ium, and that the risk among women with both muta-
tions is disproportionately higher than that among
women with only one mutation [142]. A calculation of
the positive predictive value for each genetic defect,
assuming an underlying rate of VTE of 0.67 per 1000 preg-
nancies in Western populations gave values of 1:500 for
FV Leiden mutation, 1:200 for the prothrombin-gene
mutation, and 4.6:100 for the combination of the two
defects.
Further insight into the risk of thrombosis in previously
symptom-free women with FV Leiden mutation has been
provided in a study of 43 women from symptomatic fam-
ilies. Overall, the incidence of pregnancy-associated
thrombosis was 14 percent [157], but it appears that the
risk may be higher postpartum. McColl and colleagues
estimated the risk of VTE in pregnancy to be 1 in 437 for
FV Leiden mutation, 1 in 113 for protein C deficiency, 1
in 2·8 for Type I (quantitative) antithrombin deficiency,
and 1 in 42 for Type II (qualitative) antithrombin defi-
ciency [160].
APCR can be caused by disorders other than FV Leiden
mutation, including antiphospholipid antibody syn-
drome and other genetic defects in the FV molecule. The
resistance can also be acquired during the second and
third trimester of a normal pregnancy as a result of
increases in FV and factor VIII and decreased protein S lev-
els [1,155,148,157]. The precise mechanism for this
"physiological" APCR is still not known, nor its contribu-
tion to the higher risk of VTE during pregnancy
[1,154,148,158]. The prothrombin mutation is associated
with elevated plasma prothrombin levels (factor II activity
>130 percent) and is present in about 2–5 percent of
healthy individuals. This mutation has been associated
with a three-fold increased risk of VTE. A higher risk of
thrombosis was found in women using oral contracep-
tives and in women with obstetric complications.(.(.
[4,6,160,162].
Hyperhomocysteinaemia is frequently associated with
homozygosity for the thermolabile variant of MTHFR
(C677T) [156] and is present in about 8–10 percent of
healthy individuals [6]. Pregnancy is associated with
decreased concentrations of homocysteine and folic acid
supplements will also lower homocysteine concentra-
tions. However, the contribution of homocysteine to VTE
in pregnancy remains unclear. Gerhardt et al revealed that
homozygosity for the C677T MTHFR mutation was not
associated with an increase in risk for VTE during preg-
nancy [142].
This may be explained by the fact that plasma homo-
cysteine concentrations decrease during pregnancy and
most pregnant women take folic acid supplements, which
ameliorate hyperhomocysteinemia [143].
Interestingly, the presence of an inherited thrombophilia
in a pregnant woman may have positive effects. FV Leiden
mutation has been associated with a reduced risk of intra-
partum bleeding complications, conferring a possible sur-
vival advantage for carriers [161].
The management of thrombophilia during 
pregnancy
The management of thrombophilia during pregnancy
encompasses primary thromboprophylaxis in asympto-
matic women, secondary prophylaxis of recurrences in
women who have previously developed thrombosis, and
the treatment of acute thrombotic episodes. It is rather dif-
ficult to establish guidelines for antithrombotic therapy
due to the paucity of relevant and well-controlled trials.
Thus, the recommendations regarding prophylactic and
therapeutic strategies in pregnancy are largely based on
clinical trials in non-pregnant populations [163]. An addi-
tional problem in assessing the response to antithrom-
botic therapy during pregnancy is the danger of imaging
procedures. An objective diagnosis of VTE during preg-
nancy is crucial [163]. The management of women with
VTE during pregnancy is summarized in Table 3.
Table 3: Management of Women with VTE
Category Patients Recommendation
Very high risk for VTE Previous VTE on anticoagulants; VTE in current 
pregnancy; Antithrombin deficiency
LMW heparin (Enoxaparin) mg/kg Twice day OR heparin 
adjusted dose with confirmation of pregnancy
High risk for VTE Previuos VTE; Protein C, S deficiency plus family history 
of VTE;homozygote FV or prothrombin mutation; 
combined thrombophilia
LMW heparin (Enoxaparin) 40 mg/day until 6–12 weeks 
postpartum Or fixed dose heparin
Moderate risk for VTE Heterozygote FV or prothrombin mutation, PS 
deficiency, and family history VTE
Postpartum anticoagulation LMW heparin (Enoxaparin) 
40 mg/day
Relatively low risk for VTE Heterozygote FV or prothrombin mutation; no personal 
or family history VTE
Monitor for additional risks for VTEReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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The diagnosis has serious implications not only for the
immediate management of the pregnancy, but also for the
management of future pregnancies.
Heparin is currently the drug of choice for the prevention
and treatment of VTE during pregnancy, though it is grad-
ually being replaced by low-molecular-weight heparins
(LMWH). LMWHs exhibit a number of advantages over
unfractionated heparin (UFH), including improved bioa-
vailability, a longer half-life, ease of administration, no
monitoring requirement and fewer side-effects [163-169].
Animal and human studies have shown that LMWHs are
not teratogenic or fetotoxic and do not cross the placenta
[170].
Oral anticoagulants (OACs) are rarely employed during
pregnancy because of substantial side-effects
[140,145,163]. Coumarin derivatives cross the placenta
and are associated with embryopathy in 4–5 percent of
exposed fetuses, especially during the first trimester [163].
Central nervous system anomalies can occur in any tri-
mester. OACs are reserved for conditions in which the
effectiveness of heparin and LMWH may be limited. These
include the management of women with artificial heart
valves and in cases where heparin therapy is contraindi-
cated, including cases of heparin-induced thrombocyto-
penia (HIT) or skin allergy. Heparin, LMWH and
coumarin derivatives are not secreted in the breast milk
and can be given safely to nursing mothers [163].
Primary prophylaxis of thrombosis in asymptomatic 
women
In asymptomatic women with known protein C defi-
ciency, protein S deficiency, FV Leiden or prothrombin
mutation, who have never experienced VTE, we recom-
mend either clinical surveillance or prophylactic therapy
during the last weeks of pregnancy and 2–6 weeks in the
puerperium. Subcutaneous heparin, 5000 IU twice daily
or a LMWH (enoxaparin, 40 mg once daily, or dalteparin,
5000 IU daily) is used. This thromboprophylactic treat-
ment is firmly indicated in women undergoing cesarean
section. In women with AT III deficiency, the risk may be
substantially greater and prophylactic therapy is probably
indicated throughout the pregnancy. Recently, Martinelli
et al. [170], investigated the management of women dur-
ing pregnancy who are homozygote for the FV Leiden
mutation or who had both mutations of the FV Leiden
and the prothrombin gene mutations. Most cases of
thrombosis occurred in the post-partum. Compared to
controls the OR for risk for thrombosis were 41.3 and 9.2,
respectively. Therefore, they recommended that in these
women prophylaxis should be given in the postpartum
while in homozygote women for the FV Leiden mutation
prophylaxis throughout pregnancy and post-partum
should be considered [169]. Clinical surveillance is usu-
ally reserved for women who are allergic to heparin, refuse
to use heparin or LMWH, or who have experienced a pre-
vious VTE in association with a transient risk factor [163].
The effectiveness of a surveillance approach is dependent
on the early detection and treatment of VTE disease, espe-
cially before the development of pulmonary embolism.
Compression stockings, which are effective in women
with recurrent DVT, may be useful in pregnancy and
should be recommended to women with previous DVT or
varicose veins [171].
Secondary prophylaxis in women with previous thrombosis
All patients with a personal or family history of VTE
should be considered for antenatal prophylaxis and be
screened for a thrombophilia. The two general approaches
recommended for pregnant women with previous VTE are
active prophylactic therapy with heparin or LMWH and
clinical surveillance [143,163]. Thromboprophylaxis is
firmly indicated for women who exhibit additional risk
factors such as hyperemesis, obesity, immobilization or
surgery, and particularly if they have pre-eclampsia or
concurrent medical conditions associated with thrombo-
sis, such as nephrotic syndrome, inflammatory bowel dis-
ease, or infection.
Women with thrombophilia and a history of previous
VTE should receive thromboprophylaxis during preg-
nancy and the puerperium [172]. Symptom-free carriers
of thrombophilia require special consideration. The risk
of thrombosis varies with the type of thrombophilia and
currently no controlled guidelines are available. Some
investigators find it useful to risk stratify patients as low
risk or high risk to help guide clinical evaluation. Asymp-
tomatic patients at high risk of VTE may be defined as
those with ATIII deficiency, more than one thrombophilic
anomaly or a homozygote mutation, and those with first
degree relatives who have experienced severe VTE. All
other patients are considered low risk.
The treatment of an acute thrombotic episode
Acute DVT during pregnancy in women with or without
thrombophilia is usually treated with full dose intrave-
nous heparin for 5–10 days, followed by maintenance
subcutaneous heparin given twice daily, adjusted to
prolong the activated partial thromboplastin time (aPTT)
into the therapeutic range [163].
Changes in the metabolism and clearance of heparin dur-
ing pregnancy complicate dosing and equivalent doses of
subcutaneous heparin produce lower plasma concentra-
tions in pregnant women than in non-pregnant women
[173]. It is not clear whether the dose of heparin should
be adjusted with increasing weight [171]. Although some
centers advocate weight-adjusted doses, others recom-
mend frequent aPTT testing or measurements of anti-fac-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
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tor Xa taken four hours after injection as a guide to
reaching the desired level of 0.5–1.2 U/ml [163]. Heparin
is given until term, discontinued shortly before delivery,
and restarted in conjunction with warfarin post-partum.
Heparin is subsequently discontinued when the interna-
tional normalized ratio (INR) is 2–3. The optimal dura-
tion of post-partum warfarin therapy in women with
thrombophilia who have developed DVT during preg-
nancy is currently undefined, and no guidelines are avail-
able based on clinical trials. The duration of therapy
depends on the magnitude of risk of a recurrent VTE. Indi-
vidual risk assessment should be performed, taking into
consideration the type of thrombophilia, the presence of
multigenic defects, the extent and site of thrombosis, the
time-frame of occurrence, the history of VTE and the fam-
ily history. Low risk mothers are given prophylactic ther-
apy for a further 4–6 weeks, and patients with high risk
should receive extended thromboprophylaxis. Patients
with APS or AT III deficiency who have experienced a VTE
require indefinite treatment because of the high risk of
recurrence. LMWHs continue to replace UFH in the man-
agement of acute VTE. The recommended doses for the
treatment of VTE are shown in Table 4[175]. LMWH
should be injected subcutaneously into the abdominal
wall, and in later months of pregnancy, the anterior aspect
of the thigh. These simple, once daily, treatment regimens
offer the potential for home or outpatient treatment of
DVT, with obvious resource implications, and are feasible
in patients with proximal deep vein thrombosis who do
not require hospitalization. After therapeutic administra-
tion of LMWH for 10–14 days, a prophylactic dose of
LMWH should be continued throughout the pregnancy
and then replaced with heparin for 6–8 weeks post-par-
tum as described for UFH [140,164,168]. Published stud-
ies indicate that the effective maintenance dose of
enoxaparin is 40 mg once daily and of dalteparin, 5000 IU
once daily [163-167,175,176]. However, in certain
thrombophilic conditions these doses should be
increased depending on the risk of recurrent VTE. It has
been suggested that levels of enoxaparin, given at 40 mg
once daily, are not affected by gestational age [165], but
others report that because of increased renal clearance
during pregnancy once daily dose may not be enough
[178]. Monitoring of LMWH levels is not required, but
some investigators advocate measurements of peak anti-
factor Xa concentrations 3–6 hours after the last injection,
with the goal of achieving target plasma levels of 0.4–0.6
IU per ml [179]. The dose of LMWH should be reduced
during delivery, and the timing of administration
adjusted to allow epidural or spinal anesthesia. Epidural
anesthesia may be managed by omitting the last dose of
LMWH or by delaying placement of the epidural catheter
for 6–12 hours [157]. LMWH can be restarted 2 hours
after catheter removal [140]. Warfarin should be used
post-partum, particularly to avoid the risk of osteoporosis
associated with prolonged LMWH administration [179].
A recent systematic review of all published clinical reports
employing LMWH in at-risk pregnancies, and data from
an international interest group, reported the incidence of
recurrent VTE as 3 in 486 pregnancies [164]. No congeni-
tal malformations in the newborns were observed.
Adverse effects were generally uncommon, and the most
frequently described were minor hemorrhagic complica-
tions [164].
The risk of osteoporosis is lower in pregnant women
treated with LMWH than with UFH [166]. Insertion of a
vena caval filter may be indicated in pregnant women.
Patients with pulmonary embolism despite adequate anti-
thrombotic therapy, free-floating iliofemoral DVT, ili-
ofemoral DVT in the weeks prior to delivery, or severe
femoropopliteal DVT may benefit from filter insertion.
The clinical impression is that filters prevent pulmonary
embolism, but some patients develop significant leg
swelling despite adequate maintenance with low-dose
subcutaneous heparin. There does not appear to be any
fetal morbidity or mortality associated with filter insertion
[180].
The anti-phospholipid syndrome
The clinical manifestations of APS include DVT and PE,
coronary or peripheral artery thrombosis, cerebrovascular
or retinal vessel thrombosis and pregnancy morbidity
[181,182]. Women with no history of thrombosis or prior
fetal losses who are found to have APS during a first preg-
nancy do not need prophylactic therapy.
Table 4: Treatment of VTE during Pregnancy – Recommended LMWH Doses from Controlled Studies in Medical Patients [175]
LMWH Commercial name Recommended Dose
Dalteparin Fragmin 200 anti-factor Xa units/kg once daily
Enoxaparin Clexane, Lovenox 1.0 mg/kg twice daily or 1.5 mg/kg once daily
Nadroparin Fraxiparin 200 anti-factor Xa units/kg once daily
Tinzaparin Innohep 175 anti-factor Xa units/kg once dailyReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/111
Page 17 of 22
(page number not for citation purposes)
Women with APS who have had prior thromboses,
whether or not associated with pregnancy, must receive
thromboprophylactic therapy throughout pregnancy and
the post-partum period. The recommended therapy is
either heparin (5,000 IU b.i.d.) or LMWH and low-dose
aspirin (0.1 g per day) [183]. The dose of LMWH depends
on the risk of thrombosis. In "high-risk" patients we usu-
ally recommend LMWH at therapeutic doses, such as
those used for the treatment of DVT (enoxaparin, 1 mg per
kg b.i.d). Postpartum, LMWH is replaced by warfarin.
The treatment of an acute venous thrombosis in an APS
carrier is similar to that indicated for women with other
types of thrombophilia (described above). However, in
our opinion there are differences in the maintenance
doses and duration of prophylactic therapy required. In
women with APS, we tend to administer higher doses of
LMWH depending on the severity of the thrombotic
event, the history of previous thromboembolic events and
the antibody titer. LMWH or UFH is given until term and
discontinued shortly before delivery. After delivery, the
heparin therapy is reinstated with concomitant OAC,
which are then administered for an extended period of
time. In women with APS it is usual to recommend low
dose aspirin (0.1 g per day) in addition for the prevention
of arterial thrombosis (cerebral events). For women with
APS who present with recurrent arterial or venous throm-
botic events during pregnancy, high dose aspirin (0.3–0.5
g per day) and full therapeutic doses of UFH or LMWH are
recommended.
Arterial thrombosis during pregnancy
Stroke carries a high mortality and morbidity, and is a
severe complication during pregnancy and the puerper-
ium. Among 50 million deliveries in the USA, 17.7 cases
of stroke and 11.4 cases of intracranial venous thrombosis
occurred per 100,000 deliveries [184]. Stroke was strongly
associated with pregnancy-related hypertension and
eclampsia [185] and its incidence was increased after
delivery (relative risk, 8.7) but not during pregnancy itself
[186]. Intracranial venous thrombosis has been associ-
ated with maternal age [184]. The association of
thrombotic cerebral events and inherited thrombophilia
is still controversial. Several studies have reported that
patients with prothrombin or FV Leiden mutations are at
higher risk of developing cerebral vein thrombosis
[151,154,187]. However, other studies have failed to
show a significant link between thrombophilia and the
occurrence of cerebral venous or arterial thrombosis
[1,145,146,152,154-156,188] No studies have described
the association between thrombophilia and cerebral
ischemic events during pregnancy.
We have recently investigated twelve previously healthy
pregnant women who had transient cerebral ischemic
event during pregnancy [189]. The incidence of inherited
thrombophilia was significantly higher in the 12 women
with neurological symptoms (83 percent), compared with
healthy pregnant women matched for age, ethnicity and
smoking habits (17 percent). Hence it is possible that
pregnancy and the puerperium may precipitate arterial
thrombotic events in patients with inherited throm-
bophilia, similar to the effects of smoking and the use of
oral contraceptives. These agents were found to substan-
tially increase the relative risk of myocardial infarction
and cerebral vein thrombosis in patients with the factor II
and FV mutations [190]. We suggest that women with
transient neurological events appearing during pregnancy
should be investigated for inherited thrombophilia.
Women who develop stroke or transient focal neurologic
deficits during pregnancy should be treated for a pro-
longed period with aspirin, 0.3–0.5 g per day. Women
with APS should be treated with a combination of aspirin
and heparin or LMWH [183]. No guidelines are available
for the women with other types of thrombophilia and the
decision whether to add heparin or LMWH should be
made individually on the basis of the type of
thrombophilia, additional known risk factors, recurrence
of thrombotic events and their severity.
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